Moneycontrol
    Moneycontrol PRO
    LAMF
    LAMF

    Ranbaxy

    Jump to

    • Who makes a better suitor for Cipla and what is in it for shareholders?

      Torrent Pharma and Dr Reddy’s are among the bidders. The combined India business can surpass Sun Pharma’s from any of these two deals. Investors in both Dr Reddy’s and Cipla should wait for clarity to emerge

    • Veterans Unpacked | D.S. Brar: "Your network is your net worth, and your credibility is your currency"

    • SC holds Singh brothers guilty of contempt in Daiichi Sankyo case

    • Delhi Police arrests former Ranbaxy promoter Shivinder Singh

    • Policy| Bottle of Lies: What ails India’s drug industry

    • SC asks ex-Ranbaxy promoters to apprise how they'll comply with Rs 3500 crore arbitral award

    • Opinion | Sun Pharma: New governance structure needed to protect investors' interest

    • NCLT dismisses HDFC plea for initiating insolvency proceedings against RHC Holding

    • A message for Indian pharma: Do what you say, say what you do

    • Analysts retain buy on Sun Pharma as USFDA clears Mohali, Halol unit resolution key

    • USFDA lifts import ban on Sun Pharma's Mohali plant, shares surge 5%

    • Sun Pharma soars 6% on US FDA’s plan to lift import alert at Mohali

    • Trump policies stressful for India pharma cos: Ex-Ranbaxy CEO

    • Daiichi to shut down Indian R&D centre; 170 employees impacted

    • Nifty on Cloud Nine! 9 stocks with a high margin of safety

    • COMMENT: Is Sun Pharma suffering on account of unrelated diversification?

    • Sun Pharma, Wockhardt in news on re-inspections, lawsuits

    • Positive on ITC & ICICI Bank, says Deven Choksey

    • Look at Sun Pharma, says Gaurang Shah

    • Making Ranbaxy units cGMP compliant time consuming: Sun Pharma

    • Continue to remain opportunistic for acquisitions: Sun Pharma

    • Sun Pharma falls 6% on weak sales guidance, price pressure woes

    • Sun Pharma, Daiichi terminate transaction pacts

    • More trouble for Ranbaxy as central regulator finds deficiencies

    • CCI okays PVR-DT Cinemas deal, asks to exclude certain assets

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347